LifeMine
LI
Biotech / Biopharma
Developer of a drug discovery platform designed to elucidate human biology and create sophisticated therapeutics that attack the fundamental drivers of serious human diseases.
Founded by Gregory Verdine (Co-Founder, President & CEO), WeiQing Zhou (Co-Founder & COO), Richard Klausner (Co-Founder & Chairman)
Blended valuation$1.8B$1.8B secondary
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$4.2B
blended valuationfunding round
Feb 28, 2022$250.7MOct 5, 2026
All rounds
1 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series C | Mar 1, 2022 | $175M | $525M |
Secondary market activity
Recent buy and sell interest for LifeMine shares on the secondary market.
| Kind | Implied valuation | Price / share | Date |
|---|---|---|---|
| $926.5M | $3.60 | Sep 23, 2026 | |
| $514.7M | $2.00 | Sep 22, 2026 | |
| $4.8B | $18.74 | Sep 14, 2026 |
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 14, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.